물, 에너지 및 화학 산업의 생체촉매 해결책을 개발하는 생명 공학 회사인 환경 보건 과학 연구소 (NIEHS)에서 물의 1,4-Dioxane 처리 기술을 위해 1.5백만$ Microvi 바이오에 수여되었다.

사업의 prototype 개발 및 MB-DX ™라는 dioxane저하에 대해 생물학적 처리 기술 류의 테스트 I 단계 동안 완료된 작업은 성공적이다.

지하수 및 음용수에서 가장 많이 검출 된 유기 오염 물질 중, 1,4-Dioxane은 Thomas Mohr와 물 구역 및 1,4-Dioxane분야의 리더 Santa Clara Valley에 의해 실험 결과 미국의 식수원의 13 %에서 발견되었다.

A $1.5 million grant from the National Institute of Environmental Health Sciences (NIEHS) was awarded to Microvi Biotechnologies -- a biotechnology company that develops biocatalytic solutions in the water, energy and chemical industries -- to demonstrate at scale a novel technology for the treatment of 1,4-Dioxane in water.

This undertaking follows on the success of work completed during the Phase I grant, where a prototype was developed and tested of a first-of-its-kind biological treatment technology for dioxane degradation called MB-DX™.

Among the most widely-detected organic contaminants in groundwater and drinking water, 1,4-Dioxane has been identified in 13 percent of U.S. drinking water sources tested, according to Thomas Mohr, senior hydrologist with the Santa Clara Valley Water District and a thought leader in the field of 1,4-Dioxane.

"Available treatment solutions are expensive and energy intensive and often have inconsistent performance records,” Mohr said. "Microvi’s MB-DX™ technology uses 1,4-Dioxane degrading microbes in a way that is effective and reliable and overcomes common challenges to bioreactor performance such as system stability and clogging."

Congressman Eric Swalwell (CA-15) added, "Technological innovations like the sustainable solutions developed at Microvi are driving our economic growth in the Bay area, and I will keep advocating for strong public-private partnerships (PPPs) to support this sector."